Novavax launches study of novel H1N1 vaccine in Mexico

Novavax launches study of novel H1N1 vaccine in Mexico

Novavax, Inc. (Nasdaq: NVAX) initiated a two-stage clinical study of its virus-like-particle (VLP) H1N1 influenza vaccine in Mexico in collaboration with Avimex Laboratories (Avimex) and GE Healthcare. Avimex distributes biological and pharmaceutical products for use in Mexico and more than 25 other countries around the world. Avimex is providing financial support for the trial and is expected to distribute the H1N1 VLP vaccine in Mexico in 2010 if it is approved for commercial sale. In addition, Novavax also announced today that GE Healthcare (a unit of General Electric Company (NYSE: GE) has agreed to support this program by providing its single-use bioprocessing technologies for vaccine production.

Read the release.

Filed under: Business of Biotech, ,